Phase 2Recruiting
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy (8212-Preserved)
Phase 2, Multicentre, Randomised, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodelling in Participants With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
- Sponsor
- Novo Nordisk A/S (Industry)
- Enrolment
- 200 planned
- Conditions
- Heart Failure
- Interventions
- CDR132L; Placebo
- Ages
- adults, older adults
- Registry
- NCT06979362
From the registry
This study will look into how CDR132L (a potential new medicine) works on the structure and function of the heart in people living with heart failure. Participants will either get CDR132L or placebo (a medicine which has no effect on the body), which treatment the participants get is decided by chance. The study will last for about 60 weeks.
Primary outcomes
- Main phase: Change in normalised microRNA-132-3p (miR-132)